A current review of olanzapine's safety in the geriatric patient

From pre-clinical pharmacology to clinical data

John S. Kennedy, Frank P. Bymaster, Leslie Schuh, David O. Calligaro, George Nomikos, Christian C. Felder, Mark Bernauer, Bruce J. Kinon, Robert W. Baker, Donald Hay, H. John Roth, Martin Dossenbach, Christopher Kaiser, Charles M. Beasley, John H. Holcombe, Mark B. Effron, Alan Breier

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides a broad efficacy profile in patients with schizophrenia and acute, pure or mixed mania. Patients experience symptomatic relief of mania, anxiety, hallucinations, delusions, and agitation/aggression and reduced depressive, negative, and some cognitive symptoms. This paper will review the safety profile of OLZ, focusing on the elderly, where data are available. Method: Preclinical and clinical studies of OLZ are reviewed, with emphasis on its possible effects on the cholinergic system and the histamine H1 receptor. Weight change and related metabolic considerations, cardiac and cardiovascular safety, and motor function during treatment with OLZ are also reviewed. Results and Conclusion: In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic-like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ. Currently available clinical data suggest olanzapine is predictably safe in treating adult patients of any age with schizophrenia and acute bipolar mania, as well as in treatment of patients with some types of neurodegenerative disorders.

Original languageEnglish (US)
JournalInternational Journal of Geriatric Psychiatry
Volume16
Issue numberSUPPL. 1
StatePublished - 2001

Fingerprint

olanzapine
Clinical Pharmacology
Geriatrics
Safety
Bipolar Disorder
Schizophrenia
Histamine H1 Receptors
Neurobehavioral Manifestations
Delusions
Hallucinations
Cholinergic Antagonists
Aggression
Neurodegenerative Diseases
Cholinergic Agents
Histamine
Antipsychotic Agents
Acetylcholine
Dopamine
Serotonin
Norepinephrine

Keywords

  • Alzheimer's dementia
  • Bipolar disorder
  • Dementia
  • Diabetes
  • Geriatric
  • Olanzapine
  • Receptors
  • Safety
  • Schizophrenia

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

A current review of olanzapine's safety in the geriatric patient : From pre-clinical pharmacology to clinical data. / Kennedy, John S.; Bymaster, Frank P.; Schuh, Leslie; Calligaro, David O.; Nomikos, George; Felder, Christian C.; Bernauer, Mark; Kinon, Bruce J.; Baker, Robert W.; Hay, Donald; Roth, H. John; Dossenbach, Martin; Kaiser, Christopher; Beasley, Charles M.; Holcombe, John H.; Effron, Mark B.; Breier, Alan.

In: International Journal of Geriatric Psychiatry, Vol. 16, No. SUPPL. 1, 2001.

Research output: Contribution to journalArticle

Kennedy, JS, Bymaster, FP, Schuh, L, Calligaro, DO, Nomikos, G, Felder, CC, Bernauer, M, Kinon, BJ, Baker, RW, Hay, D, Roth, HJ, Dossenbach, M, Kaiser, C, Beasley, CM, Holcombe, JH, Effron, MB & Breier, A 2001, 'A current review of olanzapine's safety in the geriatric patient: From pre-clinical pharmacology to clinical data', International Journal of Geriatric Psychiatry, vol. 16, no. SUPPL. 1.
Kennedy, John S. ; Bymaster, Frank P. ; Schuh, Leslie ; Calligaro, David O. ; Nomikos, George ; Felder, Christian C. ; Bernauer, Mark ; Kinon, Bruce J. ; Baker, Robert W. ; Hay, Donald ; Roth, H. John ; Dossenbach, Martin ; Kaiser, Christopher ; Beasley, Charles M. ; Holcombe, John H. ; Effron, Mark B. ; Breier, Alan. / A current review of olanzapine's safety in the geriatric patient : From pre-clinical pharmacology to clinical data. In: International Journal of Geriatric Psychiatry. 2001 ; Vol. 16, No. SUPPL. 1.
@article{e945e691b36c42bebc08171a8eda86d5,
title = "A current review of olanzapine's safety in the geriatric patient: From pre-clinical pharmacology to clinical data",
abstract = "Objective: Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides a broad efficacy profile in patients with schizophrenia and acute, pure or mixed mania. Patients experience symptomatic relief of mania, anxiety, hallucinations, delusions, and agitation/aggression and reduced depressive, negative, and some cognitive symptoms. This paper will review the safety profile of OLZ, focusing on the elderly, where data are available. Method: Preclinical and clinical studies of OLZ are reviewed, with emphasis on its possible effects on the cholinergic system and the histamine H1 receptor. Weight change and related metabolic considerations, cardiac and cardiovascular safety, and motor function during treatment with OLZ are also reviewed. Results and Conclusion: In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic-like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ. Currently available clinical data suggest olanzapine is predictably safe in treating adult patients of any age with schizophrenia and acute bipolar mania, as well as in treatment of patients with some types of neurodegenerative disorders.",
keywords = "Alzheimer's dementia, Bipolar disorder, Dementia, Diabetes, Geriatric, Olanzapine, Receptors, Safety, Schizophrenia",
author = "Kennedy, {John S.} and Bymaster, {Frank P.} and Leslie Schuh and Calligaro, {David O.} and George Nomikos and Felder, {Christian C.} and Mark Bernauer and Kinon, {Bruce J.} and Baker, {Robert W.} and Donald Hay and Roth, {H. John} and Martin Dossenbach and Christopher Kaiser and Beasley, {Charles M.} and Holcombe, {John H.} and Effron, {Mark B.} and Alan Breier",
year = "2001",
language = "English (US)",
volume = "16",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A current review of olanzapine's safety in the geriatric patient

T2 - From pre-clinical pharmacology to clinical data

AU - Kennedy, John S.

AU - Bymaster, Frank P.

AU - Schuh, Leslie

AU - Calligaro, David O.

AU - Nomikos, George

AU - Felder, Christian C.

AU - Bernauer, Mark

AU - Kinon, Bruce J.

AU - Baker, Robert W.

AU - Hay, Donald

AU - Roth, H. John

AU - Dossenbach, Martin

AU - Kaiser, Christopher

AU - Beasley, Charles M.

AU - Holcombe, John H.

AU - Effron, Mark B.

AU - Breier, Alan

PY - 2001

Y1 - 2001

N2 - Objective: Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides a broad efficacy profile in patients with schizophrenia and acute, pure or mixed mania. Patients experience symptomatic relief of mania, anxiety, hallucinations, delusions, and agitation/aggression and reduced depressive, negative, and some cognitive symptoms. This paper will review the safety profile of OLZ, focusing on the elderly, where data are available. Method: Preclinical and clinical studies of OLZ are reviewed, with emphasis on its possible effects on the cholinergic system and the histamine H1 receptor. Weight change and related metabolic considerations, cardiac and cardiovascular safety, and motor function during treatment with OLZ are also reviewed. Results and Conclusion: In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic-like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ. Currently available clinical data suggest olanzapine is predictably safe in treating adult patients of any age with schizophrenia and acute bipolar mania, as well as in treatment of patients with some types of neurodegenerative disorders.

AB - Objective: Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides a broad efficacy profile in patients with schizophrenia and acute, pure or mixed mania. Patients experience symptomatic relief of mania, anxiety, hallucinations, delusions, and agitation/aggression and reduced depressive, negative, and some cognitive symptoms. This paper will review the safety profile of OLZ, focusing on the elderly, where data are available. Method: Preclinical and clinical studies of OLZ are reviewed, with emphasis on its possible effects on the cholinergic system and the histamine H1 receptor. Weight change and related metabolic considerations, cardiac and cardiovascular safety, and motor function during treatment with OLZ are also reviewed. Results and Conclusion: In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic-like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ. Currently available clinical data suggest olanzapine is predictably safe in treating adult patients of any age with schizophrenia and acute bipolar mania, as well as in treatment of patients with some types of neurodegenerative disorders.

KW - Alzheimer's dementia

KW - Bipolar disorder

KW - Dementia

KW - Diabetes

KW - Geriatric

KW - Olanzapine

KW - Receptors

KW - Safety

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0002219724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002219724&partnerID=8YFLogxK

M3 - Article

VL - 16

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - SUPPL. 1

ER -